3.7 Incorporation of SM-102 into Lipo 20:0 BPD-PC improves tumor control following 690 nm light irradiation in vivo To evaluate whether in vitro enhancements in phototoxicity and photochemical ICD induction by SM-102 incorporation can translate to improved anti-tumor responses in vivo, we compared Lipo 20:0 BPD-PC (SM-102) and Lipo 20:0 BPD-PC (without SM-102) in an immune-cold syngeneic murine PDAC model following 690 nm light irradiation
Lead times and consolidated shipping windows can be locked at the quote stage
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H
It's anticipated that the new standard in efficacy, commanding top-tier pricing and enormous R&D, will transition from dual agonists (e.g., tirzepatide) to triple agonists, and every single Big Pharma player will be invested